作者: Abd Manan, Teh Sabariah Binti ; Bachi', Nur Aina ; Abdullah, Nor Azura ; Ahmad, Amirrudin ; Wan Rasdi, Nadiah ; Mohd Hanafiah, Zarimah ; Mohd Kamal, Nur Liyana ; Beddu, Salmia ; Abd Hamid, Haris Hafizal ; Wan Mohtar, Wan Hanna Melini

The water stream has been reported to contain non-steroidal anti-inflammatory drugs (NSAIDs), released from households and premises through discharge from Sewage Treatment Plant (STP). This research identifies commonly consumed NSAIDs namely ibuprofen (IBU), diclofenac (DIC), ketoprofen (KET) and naproxen (NAP) in the influent wastewater from two urban catchments (i.e. 2 STPs). We expand our focus to assess the efficiency of monomer (C18) and dimer (HLB) types of sorbents in the solid phase extraction method followed by gas chromatography mass spectrometry (GCMS) analysis and optimize model prediction of NSAIDs in the influent wastewater using I-Optimal design. The ecological risk assessment of the NSAIDs was evaluated. The HLB produced reliable analysis for all NSAIDs under study (STP1: 6.7 × 10^-3 mg L^-1 to 2.21 × 10^-1 mg L^-1, STP2: 1.40 × 10^-4 mg L^-1 to 9.72 × 10^-2 mg L^-1). The C18 however, selective to NAP. Based on the Pearson proximity matrices, the DIC_HLB can be a good indicator for IBU_HLB (0.565), NAP_C18 (0.721), NAP_HLB (0.566), and KET_HLB (0.747). The optimized model prediction for KET and NAP based on DIC are successfully validated. The risk quotients (RQ) values of NSAIDs were classified as high (RQ > 1), medium (RQ, 0.1-1) and low (RQ, 0.01-0.1) risks. The optimized models are beneficial for major NSAIDs (KET and NAP) monitoring in the influent wastewater of urban domestic area. An upgrade on the existing wastewater treatment infrastructure is recommended to counteract current water security situation.

2018-03-01·Carbohydrate Polymers1区 · 化学

Structural characterization and in vitro fermentation of a novel polysaccharide from Sargassum thunbergii and its impact on gut microbiota

1区 · 化学

Article

作者: Fu, Xiong ; Ren, Beibei ; Cao, Changliang ; Huang, Qiang ; Zhang, Bin ; Li, Chao

The aim of the present study was to investigate structural characteristic and in vitro fermentation of a novel polysaccharide named ST-P2 from Sargassum thunbergii by human fecal inoculums, and its impact on human colonic microbiota. The results showed that ST-P2 was homogeneous with molecular weight of 48,788 Da, and consisted of arabinose, galactose, glucose, xylose, and mannose. The main linkage types were identified as (1 → 5)-α-L-Araf, (1 → 3)-α-L-Manp, (1 → 3,6)-β-D-Galp, (1 → 6)-α-D-Glcp, and (1 → 3)-β-D-Xylp, respectively. After 48 h fermentation, 67.83 ± 1.15% of total carbohydrate was utilized by colonic microbiota. The pH value in the fecal culture significantly decreased from 6.09 ± 0.11 to 4.70 ± 0.04. The concentrations of total short chain fatty acids, acetic, propionic, n-butyric and n-valeric acids significantly increased compared to the blank. ST-P2 could remarkably modulate the composition and abundance of beneficial microbiota. These results suggest that ST-P2 could potentially be a functional food aimed at promoting the gut health.

2015-05-01·Ecotoxicology and Environmental Safety2区 · 环境科学与生态学

Impact of wastewater from different sources on the prevalence of antimicrobial-resistant Escherichia coli in sewage treatment plants in South India

2区 · 环境科学与生态学

Article

作者: Toshiyuki Tsutsui ; Derrick Ian Joshua ; Masahiro Kusumoto ; Nobuyoshi Yamashita ; Keerthi S. Guruge ; Valipparambil P. Prabhasankar ; Ken ichi Lee ; Kurunthachalam Kannan ; Keshava Balakrishna ; Haruna Otagiri ; Sachi Taniyasu ; Takehisa Yamamoto ; Taketoshi Iwata ; Masato Akiba ; Indira Bairy ; Hironobu Senba

The sewage treatment plant (STP) is one of the most important interfaces between the human population and the aquatic environment, leading to contamination of the latter by antimicrobial-resistant bacteria. To identify factors affecting the prevalence of antimicrobial-resistant bacteria, water samples were collected from three different STPs in South India. STP1 exclusively treats sewage generated by a domestic population. STP2 predominantly treats sewage generated by a domestic population with a mix of hospital effluent. STP3 treats effluents generated exclusively by a hospital. The water samples were collected between three intermediate treatment steps including equalization, aeration, and clarification, in addition to the outlet to assess the removal rates of bacteria as the effluent passed through the treatment plant. The samples were collected in three different seasons to study the effect of seasonal variation. Escherichia coli isolated from the water samples were tested for susceptibility to 12 antimicrobials. The results of logistic regression analysis suggest that the hospital wastewater inflow significantly increased the prevalence of antimicrobial-resistant E. coli, whereas the treatment processes and sampling seasons did not affect the prevalence of these isolates. A bias in the genotype distribution of E. coli was observed among the isolates obtained from STP3. In conclusion, hospital wastewaters should be carefully treated to prevent the contamination of Indian environment with antimicrobial-resistant bacteria.

项与 STP-2 相关的新闻（医药）

2024-01-17

·Pharmaceutical Technology

Stalica raises $17.5m to advance neurology programmes

The ASD pipeline consists of 127 drugs spanning all stages of development, with only 7% of drugs present in Phase III and 11.8% in Phase II clinical development. Image Credit: Alex and Maria photo / Shutterstock. Switzerland-based Stalica has raised $17.5m in Series B financing to fund clinical trials for its neuropsychiatric and neurological disorders pipeline. The clinical programmes that the company plans to use the Series B proceeds include the fixed-dose combination drug STP1 and mavoglurant (STP7). Furthermore, the company will also strengthen the data package for STP2. Stalica’s clinical pipeline STP1 is a fixed dose combination of ibudilast, a phosphodiesterase (PDE) 4/3 inhibitor, and bumetanide, a sodium (Na)- potassium (K)- chloride (Cl) cotransporter (NKCC) 1 agonist. Stalica is developing the precision therapy as a treatment for autism spectrum disorder (ASD) in a specific sub-group of patients, phenotype 1 (Phen1). Phen1 patients have been identified by Stalica and validated using two independent clinical observational/bio-sampling studies (NCT05590715 and NCT04644003). The company is planning a Phase II trial for STP1 in patients with ASD, the preparation of which will be funded by the proceeds from the current financing round. Mavoglurant is a negative allosteric modulator of the glutamate receptor 5 (mGluR5). Stalica signed an in-licencing agreement with Novartis to develop the drug as a treatment for substance-use disorders and neurodevelopmental disorders (NDDs) in January 2023. As per the agreement, the company is entitled to receive up to $270m in upfront and milestone-based payments along with royalties on net sales. The company is planning a Phase III trial for mavoglurant in patients with cocaine use disorder in 2025. The trial will be funded by the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH). It is expected to enrol up to 330 patients. STP2 is a stabilised synthetic form of sulforaphane. Stalica acquired the rights to the therapy from the UK-based Evgen Pharma in October 2022. Stalica is developing STP2 as a treatment for ASD in Phen2 sub-population. The company plans to start Phase II trial for the therapy in 2023. ASD landscape The total diagnosed prevalence of ASD was more than 9.81 million in 2023 and is expected to be approximately 9.65 million diagnosed prevalent cases of ASD in 2028, as per a 2023 Globaldata report . The ASD pipeline consists of 127 drugs spanning all stages of development, with only 7% of drugs present in Phase III and 11.8% in Phase II clinical development. GlobalData is the parent company of Pharmaceutical Technology . In November 2023, SciSparc started a clinical trial for SCI-210 to treat ASD symptoms in children. SCI-210 is a combination of cannabidiol (CBD) and palmitoylethanolamide. The trial is expected to enrol 60 patients aged five and 18 years. Apart from ASD treatment, strides have been made in developing diagnostics for the disorder. In September 2023, EarliTech positive data from two studies showing the efficacy and accuracy of its EarliPoint Evaluation device in diagnosing and assessing autism in children aged 30 months and older.

临床2期临床3期

2022-07-19

·BioSpace

STALICLA Awarded EUR 1.7 Million to Lead Computational Drug Repositioning Activities in EU-funded REPO4EU Project

STALICLA will be a leading contributor to the Euro-Global Platform for Mechanism-based Drug Repurposing (REPO4EU) consortium, with a EUR 1.7 million budget allocated to STALICLA Discovery and Data Science (DDS) unit GENEVA--(BUSINESS WIRE)-- REPO4EU consortium seeks to address the urgent need for new cost-effective therapies, as well as to improve existing treatments through international cooperation, pooling research and innovation expertise. A total of EUR 22 million grant has been awarded to REPO4EU by EU (HORIZON-HLTH-DISEASE-2021-04-02) within the Key Strategic Orientation KSO-D ‘Creating a more resilient, inclusive and democratic European society’ of Horizon Europe’s Strategic Plan 2021-2024. REPO4EU is one of the only two projects retained among 13 full consortium applications. STALICLA DDS was granted a EUR 1.7 million budget over 6 years to act as leader for in silico drug repositioning work tasks. STALICLA DDS will bring its technology and know-how to analyze biosample and clinical data from hundreds of patients with neurodevelopmental disorders (NDDs). Lynn DURHAM, STALICLA’s CEO stated that “STALICLA is thrilled to be leading the REPO4EU in silico drug repositioning work task project. This achievement is a strong acknowledgement of STALICLA’s technology and expertise in accelerating precision medicine discovery for patients with complex diseases.” It takes on average 15 years for promising drug candidates to reach the market. Repositioning investigational medicinal products beyond their original pursued indication is an efficient strategy to reduce timelines, costs and attrition in drug development. STALICLA will contribute to REPO4EU its unique know-how of in silico systems biology and artificial intelligence applications for patient stratification and treatment identification. For more information see: REPO4EU consortium web and twitter The funding call and info on the resolution of the call About STALICLA STALICLA is a clinical stage biotech company advancing the first clinically validated precision medicine platform for patients with Neurodevelopmental Disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD). STALICLA has already identified and validated clinically and biologically several subgroups of patients with ASD and corresponding treatment candidates. STP1, STALICLA’s first lead treatment, aims to serve a first biological subgroup of patients with ASD- ASD-Phenotype 1. STP1 has successfully completed clinical Phase 1b in early 2022, showing good safety/tolerability, positive target engagement, and superiority in cognition endpoints in treatment versus placebo groups. In 2023, STP1 will enter Phase 2; STP2, a phase 2 ready compound tailored for the treatment of ASD-Phenotype 2 patients will also be entering Phase 2. For more information, please visit: . View source version on businesswire.com: Contacts info@stalicla.com +41 22 545 12 42 Source: STALICLA View this news release online at:

100 项与 STP-2 相关的药物交易

登录后查看更多信息